GlassScriptPhysician profile
Andrew Berry
NPI 1487049193
$2,663.41
in general payments reported to CMS, 2019-2025
25 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.41 · 2020: $140 · 2021: $87.24 · 2022: $444 · 2023: $20.87 · 2024: $287 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $507.10 | 2020-2025 | Entyvio, Eohilia |
| Abbvie INC. | $477.16 | 2021-2025 | Rinvoq |
| Madrigal Pharmaceuticals | $343.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $209.97 | 2024-2025 | Tremfya |
| Daiichi Sankyo INC. | $171.20 | 2021-2022 | |
| Gilead Sciences, INC. | $117.64 | 2020 | |
| Ardelyx, INC. | $91.62 | 2025 | Ibsrela |
| Lilly USA, LLC | $87.97 | 2024-2025 | Omvoh |
| Genzyme Corporation | $87.39 | 2024-2025 | |
| Olympus America INC. | $71.98 | 2025 | Visiglide, Disposable Emr Kit, Single Use Electrosurgical Hemostatic Forceps |
| Olympus Corporation of The Americas | $71.41 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $71.01 | 2025 | Iqirvo |
| Qol Medical, LLC | $51.15 | 2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $39.94 | 2021-2022 | |
| Boston Scientific Corporation | $39.25 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $39.23 | 2025 | Dupixent |
| Echosens North America, INC. | $28.20 | 2022-2025 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $26.08 | 2025 | Voquezna |
| Amgen INC. | $26.07 | 2021 | |
| Aimmune Therapeutics, INC. | $23.31 | 2025 | Vowst |
| Tersera Therapeutics LLC | $21.34 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.39 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Braintree Laboratories, INC. | $15.45 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.